Cullen/Frost Bankers, Inc. 2seventy Bio, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 3 shares of TSVT stock, worth $7. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3Holding current value
$7% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TSVT
# of Institutions
131Shares Held
46MCall Options Held
122KPut Options Held
19.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$14.6 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.29MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$9.22 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$8.97 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$7.09 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $92.8M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...